Cocaine hampers HIV

      Just two studies presented at the conference were devoted to studying the effect of cocaine on HIV-positive patients. Rapporteur on both acted immunologist Joumana Zeidan of the Florida Institute for the development of vaccines and gene therapy. The objects of  first  studies were 18 HIV-infected patients with the same level of T-lymphocytes, each of whom regularly used cocaine. It was found that cocaine dramatically reduces the function of the thymus gland (thymus), which mature T cells, which play a key role in the immune response to the virus.

    The second study was conducted gene analysis showed that cocaine gives the signal connection between the incidence of virus cells and the thymus, resulting in the overproduction of regulatory T cells that suppress the immune response, at the expense of T-helper cells.

The immune system of elite controllers blocking a key protein in the virus

        About one percent of people infected with human immunodeficiency virus, the so-called elite controllers, even in the absence of treatment is not going to symptoms of AIDS.  

    Virologist and immunologist (Philip Mwimanzi) from Simon Fraser University (Vancouver, Canada) and his colleagues compared the virus isolated in 45 elite controllers and 48 patients in whom the disease progresses in a standard way. It was found that the protein Nef (Negative Regulatory Factor), which plays an important role in the development of HIV, the virus isolated from elite controllers, practically not functioning. Compared to a "normal" such Nef can not enter cells and replicate. In addition, the "elite" Nef can inhibit the expression of proteins on the surface of antigen-presenting cells. All this allows the immune system to control the virus, according to the study authors.

STANOZOLOL (Winstrol)

   

Stanozolol is a man-made steroid, similar to the a naturally occurring steroid testosterone. Stanozolol is used in - hereditary angioedema, which causes episodes of swelling of the face, extremities, genitals, bowel wall, and throat. Stanozolol may decrease the frequency and severity of these attacks.

There were no interactions found in our database between Nolvadex and stanozolol

However, this does not necessarily mean no interactions exist. ALWAYS consult with your doctor or pharmacist.

Nolvadex is in the following drug classes: hormones/antineoplastics, selective estrogen receptor modulators.
Nolvadex is used to treat the following conditions: Breast Cancer, Breast Cancer, Adjuvant, Breast Cancer, Male, Breast Cancer, Metastatic, Breast Cancer, Palliative, McCune-Albright Syndrome, Precocious Puberty.
Stanozolol is a member of the drug class androgens and anabolic steroids. Stanozolol is used to treat Angioedema.

Medications for heartburn cause HIV-infected bone fragility

      Normalize stomach acid drugs - proton pump inhibitors (PPIs) such as Prilosec (PRILOSEC, the active ingredient omeprazole) and Nexium (Nexium, the active ingredient esomeprazole), increase the risk of bone fractures in HIV-infected patients. This conclusion was made by researchers from Yale University based on the examination of more than forty thousand HIV-infected men of middle age.

     As reported by the speaker, (Julie Womack), those who regularly took PPIs, on average twice as often broken limbs, than those who did not take the drugs. The study authors suggest that the mechanism of action of PPIs with locking parientalnyh cells of the gastric mucosa, prevents bone regeneration processes and thus causes brittle bones.

Therapeutic HIV Vaccine 'Proof of Concept'

   A small clinical trial of a therapeutic HIV vaccine temporarily lowered viral levels in HIV-positive participants. While the study is highly preliminary, it gave the Spanish researchers,  a “proof of concept,” suggesting that their strategy may one day lead to a “functional cure,” in which people with HIV could suppress the virus without the need for daily antiretrovirals (ARVs). 

   The researchers created vaccine effect by modifying the patients’ own dendritic cells. These are immune cells that prompt CD4s to fight pathogens—but they can also carry HIV and transmit the virus to CD4 cells. The scientists pulsed the participants’ dendritic cells with HIV that had been drawn from their bloodstream and deactivated with heat.  Out of 36 participants, all of whom were taking long-term ARV therapy, 24 were randomly assigned to receive three injections of the manipulated cells and 12 received three doses of ordinary dendritic cells. Afterward, all participants stopped taking ARVs for 48 weeks. 

     After 12 weeks of ARV cessation, 12 out of the 22 participants who remained in the treatment cohort had a 10-fold reduction or greater in what’s known as a plasma viral load set point, while only one out of 11 in the control group experienced such a benefit. Following an additional 12 weeks, seven out of 20 participants still within the active therapy group maintained a 10-fold reduction in their viral load set point, while none in the control group experienced any sustained therapeutic effect. The viral load reduction was consistently associated with a rise in CD4 counts.

     The vaccine proved safe and well tolerated. Eventually, however, all the participants saw their viral loads rise again.